India’s leading pharma company Dr Reddy’s Laboratories said that “The US health regulator has asked the company to take voluntary action against its Duvvada Facility.”
In a filing with BSE, Dr Reddy’s said, “Further to our intimation dated on August 20, 2019. With regard to the audit of our Formulations Manufacturing Plant (Vizag SEZ Plant 1 – FTO 7) at Duvvada, Visakhapatnam.”
“We would like to inform you that we have been notified by the USFDA that the inspection classification of the above-referred facility is determined as Voluntary Action Initiated (VAI),” the filing added.
